The public record for this applicant centers on one recent premarket notification. FDA records linked by MedtechLedger show K262235 received on July 1, 2026, and decided on September 4, 2026, as substantially equivalent under the traditional review track, with a summary statement on file. The device family is listed as the ApexCut™ Blade with Automated EM Tracking across six model numbers, and the applicant is Medtronic Xomed, Inc. of Jacksonville, Florida, per the filing address. The submission sits in product code PGW, regulation number 882.4560, with the classification name Ear, Nose, And Throat Stereotaxic Instrument and Neurology as the advisory committee description. [1][2][7]

The cleared device family and its stated scope

The FDA clearance letter identifies the trade name as ApexCut™ Blade with Automated EM Tracking and lists six model numbers: 187BL4012EM, 187BL4040EM, 187BL4060EM, 187BL2975EM, 187BL3590EM, and 187BL4000LEM. The same letter describes the device type as a sterile, single-use navigated powered ENT blade and, in a comparison line, a sterile, single-use navigated shaver blade. The stated intended use covers incision and removal of soft and hard tissue or bone in general otorhinolaryngology, head and neck, and otoneurological surgery. [1][2]

Medtronic's own product page describes the ApexCut™ EM navigated blades as factory-calibrated, single-use navigated blades for ENT sinus procedures, designed for setup with Medtronic image-guided navigation systems. The page names two design features: a tooth-to-tooth mouth design and distal-to-proximal cutting that aligns suction and cutting direction. These are manufacturer descriptions of design, not clinical results. [5]

Filing details and review pathway

The 510(k) database entry records K262235 as a traditional submission, not a third-party review, with the summary as the statement type and an empty expedited review flag. The decision code is SESE, described as Substantially Equivalent, dated September 4, 2026. The review advisory committee is listed as EN, while the advisory committee description reads Neurology. [1][7]

The applicant address in the filing is 6743 Southpoint Dr. N., Jacksonville, Florida 32216, with Penny Goodman listed as contact and senior regulatory affairs specialist. That is a correspondence address in a regulatory filing and does not establish a corporate headquarters. The filing does not state ownership, parentage, or commercial availability. [1][2]

How the blades fit the ENT navigation catalog

The 2026–2027 Medtronic ENT product catalog places navigation solutions alongside powered ENT systems and components, including the IPC™, XPS Nexus™, microdebriders, and Hydrodebrider™. A catalog note states that the Medtronic family of navigation systems, StealthStation™ ENT, Fusion™, and FUSION™ Compact, works with the instrument sets, balloons, suctions, and blades listed on those pages. The catalog also references StraightShot™ automated EM tracking blades in the navigation section. [3]

A Medtronic news release dated October 7, 2026, announces FDA clearance of the ApexCut™ EM navigated blades for sinus surgery and describes connecting powered instrumentation and navigation. The release defines its efficiency language as reduction of clogging and minimized interruptions attributed to blade cutting design and FlexMetric™ technology in curved blades. Its footnote cites non-clinical testing measuring grams resected of simulated material before first clog against Medtronic Tricut, RAD, and Quadcut blades, and states that non-clinical testing is not indicative of clinical results. [8]

What the collection shows and what it does not

As of the snapshot date, the linked collection holds one 510(k) record with one SESE decision, and the explicitly smaller record sample likewise holds one record with one SESE decision. These counts describe the indexed filings only; they are not measures of total portfolio size, sales, or safety performance. A third-party device database lists K262235 as active with no expiry and reports no FDA recalls in its synced data, which is that publisher's index rather than an FDA determination. [1][9]

The same third-party database lists ApexCut EM Navigated Blades under Class IIa CE/MDR with GUDID on market. That entry is attributed to deviCERTS and is not corroborated by the FDA sources here. No source in this set documents clinical outcomes, patient selection, or instructions for use beyond the stated intended use. [9]